Natural and vaccine-induced B cell-derived systemic and mucosal humoral immunity to human papillomavirus

References

• Doorbar J, Egawa N, Griffin H, et al. Human papillomavirus molecular biology and disease association. Rev Med Virol. 2015 Mar;25(Suppl 1):2–23.
   PubMed Web of Science ®Google Scholar
• Mboumba Bouassa RS, Prazuck T, Lethu T, et al. Cervical cancer in sub-Saharan Africa: a preventable noncommunicable disease. Expert Rev Anti Infect Ther. 2017;15(6):613–627.
   PubMed Web of Science ®Google Scholar
• Chesson HW, Dunne EF, Hariri S, et al. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis. 2014;41(11):660–664.
   PubMed Web of Science ®Google Scholar
• de Villiers EM, Fauquet C, Broker TR, et al. Classification of papillomaviruses. Virology. 2004;324:17–27.
   PubMed Web of Science ®Google Scholar
• Zur Hausen H. Papillomavirus infections-a major cause of human cancers. Biochim Biophys Acta. 1996;1288:F55–78.
   PubMed Web of Science ®Google Scholar
• IARC. IARC monographs on the evaluation of carcinogenic risks to humans, Vol. 90. Human papillomaviruses. Lyon; 2007. (ISBN 978 92 832 1290 4).
   Google Scholar
• Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518–527.
   PubMed Web of Science ®Google Scholar
• Bouvard V, Baan R, Straif K, et al. A review of human carcinogens–Part B: biological agents. Lancet Oncol. 2009;10(4):321–322..
   PubMed Web of Science ®Google Scholar
• de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010 Nov;11(11):1048–1056.
   PubMed Web of Science ®Google Scholar
• Stier EA, Chigurupati NL, Fung L. Prophylactic HPV vaccination and anal cancer. Hum Vaccin Immunother. 2016 Jun;12(6):1348–1351.
   PubMed Web of Science ®Google Scholar
• Stanley M. Immunobiology of HPV and HPV vaccines. Gynecol Oncol. 2008 May;109(2 Suppl):S15–21.
   PubMed Web of Science ®Google Scholar
• Roden RBS, Stern PL. Opportunities and challenges for human papillomavirus vaccination in cancer. Nat Rev Cancer. 2018 Apr;18(4):240–254.
   PubMed Web of Science ®Google Scholar
• Bourgault Villada I, Moyal Barracco M, Ziol M, et al. Spontaneous regression of grade 3 vulvar intraepithelial neoplasia associated with human papillomavirus-16-specific CD4(+) and CD8(+) T-cell responses. Cancer Res. 2004 Dec 1;64(23):8761–8766.
   PubMed Web of Science ®Google Scholar
• Mollers M, Vossen JM, Scherpenisse M, et al. Review: current knowledge on the role of HPV antibodies after natural infection and vaccination: implications for monitoring an HPV vaccination programme. J Med Virol. 2013 Aug;85(8):1379–1385.
   PubMed Web of Science ®Google Scholar
• Stanley MA, Sterling JC. Host responses to infection with human papillomavirus. Curr Probl Dermatol. 2014;45:58–74.
   PubMedGoogle Scholar
• Mboumba Bouassa RS, Mbeko Simaleko M, Camengo SP, et al. Unusual and unique distribution of anal high-risk human papillomavirus (HR-HPV) among men who have sex with men living in the Central African Republic. PLoS One. 2018;13(5):e0197845.
   PubMed Web of Science ®Google Scholar
• Sauvageau C, Dufour-Turbis C. HPV vaccination for MSM: synthesis of the evidence and recommendations from the Québec Immunization Committee. Hum Vaccin Immunother. 2016 Jun 2;12(6):1560–1565.
   PubMed Web of Science ®Google Scholar
• Harper DM, DeMars LR. HPV vaccines - A review of the first decade. Gynecol Oncol. 2017 Jul;146(1):196–204.
   PubMed Web of Science ®Google Scholar
• Pinto LA, Dillner J, Beddows S, et al. Immunogenicity of HPV prophylactic vaccines: serology assays and their use in HPV vaccine evaluation and development. Vaccine. 2018 Aug 6;36(32 Pt A):4792–4799.
   PubMed Web of Science ®Google Scholar
• Cladel NM, Peng X, Christensen N, et al. The rabbit papillomavirus model: a valuable tool to study viral-host interactions. Philos Trans R Soc Lond B Biol Sci. 2019 May 27;374(1773):20180294.
   PubMed Web of Science ®Google Scholar
• Fausch SC, Da Silva DM, Rudolf MP, et al. Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses. J Immunol. 2002 Sep 15;169(6):3242–3249.
   PubMed Web of Science ®Google Scholar
• Yang R, Wheeler CM, Chen X, et al. Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer. J Virol. 2005 Jun;79(11):6741–6750.
   PubMed Web of Science ®Google Scholar
• Da Silva DM, Fausch SC, Verbeek JS, et al. Uptake of human papillomavirus virus-like particles by dendritic cells is mediated by Fcgamma receptors and contributes to acquisition of T cell immunity. J Immunol. 2007 Jun 15;178(12):7587–7597.
   PubMed Web of Science ®Google Scholar
• Michael KM, Waterboer T, Sehr P, et al. Seroprevalence of 34 human papillomavirus types in the German general population. PLoS Pathog. 2008 Jun 20;4(6):e1000091.
   PubMed Web of Science ®Google Scholar
• Dillner J, Andersson-Ellstrom A, Hagmar B, et al. High risk genital papillomavirus infections are not spread vertically. Rev Med Virol. 1999;9:23–29.
   PubMed Web of Science ®Google Scholar
• Syrjanen S, Puranen M. Human papillomavirus infections in children: the potential role of maternal transmission. Crit Rev Oral Biol Med. 2000;11:259–274.
   PubMedGoogle Scholar
• Cason J, Mant CA. High-risk mucosal human papillomavirus infections during infancy & childhood. J Clin Virol. 2005;32(Suppl 1):S52–58.
   PubMedGoogle Scholar
• Brandtzaeg P. Overview of the mucosal immune system. Curr Top Microbiol Immunol. 1989;146:13–25.
   PubMed Web of Science ®Google Scholar
• Mestecky J, Russell MW. Mucosal immunoglobulins and their contribution to defence mechanisms: an overview. Biochem Soc Trans. 1997;25:457–462.
   PubMed Web of Science ®Google Scholar
• Chabeda A, Yanez RJR, Lamprecht R, et al. Therapeutic vaccines for high-risk HPV-associated diseases. Papillomavirus Res. 2018 Jun;5:46–58.
   PubMed Web of Science ®Google Scholar
• Brandtzaeg P, Nilssen DE, Rognum TO, et al. Ontogeny of the mucosal immune system and IgA deficiency. Gastroenterol Clin North Am. 1991;20:397–439.
   PubMed Web of Science ®Google Scholar
• Brandtzaeg P. Molecular and cellular aspects of the secretory immunoglobulin system. APMIS. 1995;103:1–19.
   PubMed Web of Science ®Google Scholar
• Russell MW, Mestecky J. Humoral immune responses to microbial infections in the genital tract. Microbes Infect. 2002;4:667–677.
   PubMed Web of Science ®Google Scholar
• Holmgren J. Mucosal immunity and vaccination. FEMS Microbiol Immunol. 1991;89:1–10.
   Google Scholar
• Kutteh WH, Blackwell RE, Gore H, et al. Secretory immune system of the female reproductive tract II. Local immune system in normal and infected fallopian tube. Fertil Steril. 1990;54:51–55.
   PubMed Web of Science ®Google Scholar
• Brandtzaeg P. Mucosal immunity in the female genital tract. J Reprod Immunol. 1997;36:23–50.
   PubMed Web of Science ®Google Scholar
• Brandtzaeg P, Baekkevold ES, Farstad IN, et al. Regional specialization in the mucosal immune system: what happens in the microcompartments? Immunol Today. 1999;20:141–151.
   PubMedGoogle Scholar
• Kutteh WH, Mestecky J. Secretory immunity in the female reproductive tract. Gynecol Oncol. 1994;31:40–46.
   Google Scholar
• Hoglund P, Karre K, Klein G. The uterine cervix-A new member of the family of immunologically exceptional sites? Cancer Immun. 2003;3:6.
   PubMedGoogle Scholar
• Hagensee ME, Koutsky LA, Lee SK, et al. Detection of cervical antibodies to human papillomavirus type 16 (HPV-16) antigens in relation to detection of HPV-16 DNA and cervical lesions. J Infect Dis. 2000;181:1234–1239.
   PubMed Web of Science ®Google Scholar
• Hart DN. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood. 1997;90:3245–3287.
   PubMed Web of Science ®Google Scholar
• McArdle JP, Muller HK. Quantitative assessment of Langerhans’ cells in human cervical intraepithelial neoplasia and wart virus infection. Am J Obstet Gynecol. 1986;154:509–515.
   PubMed Web of Science ®Google Scholar
• Tay SK, Jenkins D, Maddox P, et al. Subpopulations of Langerhans’ cells in cervical neoplasia. Br J Obstet Gynaecol. 1987;94:10–15.
   PubMedGoogle Scholar
• Hughes RG, Norval M, Howie SE. Expression of major histocompatibility class II antigens by Langerhans’ cells in cervical intraepithelial neoplasia. J Clin Pathol. 1988;41:253–259.
   PubMed Web of Science ®Google Scholar
• Viac J, Guerin-Reverchon I, Chardonnet Y, et al. Langerhans cells and epithelial cell modifications in cervical intraepithelial neoplasia: correlation with human papillomavirus infection. Immunobiology. 1990;180:328–338.
   PubMed Web of Science ®Google Scholar
• Mestecky J, Fultz PN. Mucosal immune system of the human genital tract. J Infect Dis. 1999;179:S470–4.
   PubMed Web of Science ®Google Scholar
• Buck CB, Day PM, Trus BL. The papillomavirus major capsid protein L1. Virology. 2013;445:169–174.
   PubMed Web of Science ®Google Scholar
• Wang JW, Roden RB. L2, the minor capsid protein of papillomavirus. Virology. 2013;445:175–186.
   PubMed Web of Science ®Google Scholar
• Kirnbauer R, Booy F, Cheng N, et al. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A. 1992;89:12180–12184.
   PubMed Web of Science ®Google Scholar
• Carter JJ, Koutsky LA, Wipf GC, et al. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis. 1996;174:927–936.
   PubMed Web of Science ®Google Scholar
• Carter JJ, Wipf GC, Madeleine MM, et al. Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera. J Virol. 2006;80:4664–4672.
   PubMed Web of Science ®Google Scholar
• Kreimer AR, Johansson M, Yanik EL, et al. Kinetics of the human papillomavirus type 16 E6 antibody response prior to oropharyngeal cancer. J Natl Cancer Inst. 2017 Aug 1;109(8). DOI:10.1093/jnci/djx005.
   Google Scholar
• Lang Kuhs KA, Kreimer AR, Trivedi S, et al. Human papillomavirus 16 E6 antibodies are sensitive for human papillomavirus-driven oropharyngeal cancer and are associated with recurrence. Cancer. 2017 Nov 15;123(22):4382–4390.
   PubMed Web of Science ®Google Scholar
• Zhang X, Li S, Modis Y, et al. Functional assessment and structural basis of antibody binding to human papillomavirus capsid. Rev Med Virol. 2016 Mar;26(2):115–128..
   PubMed Web of Science ®Google Scholar
• Dillner J, Wiklund F, Lenner P, et al. Antibodies against linear and conformational epitopes of human papillomavirus type 16 that independently associate with incident cervical cancer. Int J Cancer. 1995;60(3):377–382..
   PubMed Web of Science ®Google Scholar
• Plevka P, Lim PY, Perera R, et al. Neutralizing antibodies can initiate genome release from human enterovirus 71. Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):2134–2139.
   PubMed Web of Science ®Google Scholar
• Partridge JM, Koutsky LA. Genital human papillomavirus infection in men. Lancet Infect Dis. 2006;6:21–31.
   PubMed Web of Science ®Google Scholar
• Clifford GM, Gallus S, Herrero R, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet. 2005;366:991–998.
   PubMed Web of Science ®Google Scholar
• Antonsson A, Forslund O, Ekberg H, et al. The ubiquity and impressive genomic diversity of human skin papillomaviruses suggest a commensalic nature of these viruses. J Virol. 2000;74:11636–11641.
   PubMed Web of Science ®Google Scholar
• Berkhout RJ, Bouwes Bavinck JN, Ter Schegget J. Persistence of human papillomavirus DNA in benign and (pre)malignant skin lesions from renal transplant recipients. J Clin Microbiol. 2000;38:2087–2096.
   PubMed Web of Science ®Google Scholar
• Scherpenisse M, Schepp RM, Mollers M, et al. van der Klis FR. Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses. PLoS One. 2013;8(9):e74797.
   PubMed Web of Science ®Google Scholar
• Dillner J. The serological response to papillomaviruses. Semin Cancer Biol. 1999;9:423–430.
   PubMed Web of Science ®Google Scholar
• Ho GY, Studentsov Y, Hall CB, et al. Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. J Infect Dis. 2002;186:737–742.
   PubMed Web of Science ®Google Scholar
• Palmroth J, Namujju P, Simen-Kapeu A, et al. Natural seroconversion to high-risk human papillomaviruses (hrHPVs) is not protective against related HPV genotypes. Scand J Infect Dis. 2010 May;42(5):379–384..
   PubMed Web of Science ®Google Scholar
• Coursaget P. Serology for human papillomavirus. Salud Publica Mex. 2003;45(Suppl 3):S361–366.
   PubMedGoogle Scholar
• Stanley MA. Immune responses to human papilloma viruses. Indian J Med Res. 2009;130(3):266–276.
   PubMed Web of Science ®Google Scholar
• Smith JF, Brownlow M, Brown M, et al. Antibodies from women immunized with Gardasil® cross-neutralize HPV 45 pseudovirions. Hum Vaccin. 2007;3:109–115.
   PubMed Web of Science ®Google Scholar
• Draper E, Bissett SL, Howell-Jones R, et al. Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera. Vaccine. 2011 Nov 3;29(47):8585–8590.
   PubMed Web of Science ®Google Scholar
• Malagón T, Drolet M, Boily MC, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(10):781–789.
   PubMed Web of Science ®Google Scholar
• Wheeler CM, Castellsagué X, Garland SM, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012 Jan;13(1):100–110..
   PubMed Web of Science ®Google Scholar
• De Vincenzo R, Ricci C, Conte C, et al. HPV vaccine cross-protection: highlights on additional clinical benefit. Gynecol Oncol. 2013;130(3):642–651.
   PubMed Web of Science ®Google Scholar
• Barzon L, Squarzon L, Masiero S, et al. Neutralizing and cross-neutralizing antibody titers induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes. Vaccine. 2014 Sep 15;32(41):5357–5362.
   PubMed Web of Science ®Google Scholar
• Bissett SL, Draper E, Myers RE, et al. Cross-neutralizing antibodies elicited by the Cervarix® human papillomavirus vaccine display a range of Alpha-9 inter-type specificities. Vaccine. 2014;32(10):1139–1146.
   PubMed Web of Science ®Google Scholar
• Giroglou T, Sapp M, Lane C, et al. Immunological analyses of human papillomavirus capsids. Vaccine. 2001;19:1783–1793.
   PubMed Web of Science ®Google Scholar
• Combita AL, Touze A, Bousarghin L, et al. Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J Virol. 2002;76:6480–6486.
   PubMed Web of Science ®Google Scholar
• Bissett SL, Mattiuzzo G, Draper E, et al. Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteins. Vaccine. 2014;32(48):6548–6555.
   PubMed Web of Science ®Google Scholar
• Cheng G, Icenogle JP, Kirnbauer R, et al. Divergent human papillomavirus type 16 variants are serologically cross-reactive. J Infect Dis. 1995;172:1584–1587.
   PubMed Web of Science ®Google Scholar
• Bissett SL, Godi A, Fleury MJ, et al. Naturally occurring capsid protein variants of human papillomavirus genotype 31 represent a single L1 serotype. J Virol. 2015 Aug;89(15):7748–7757.
   PubMed Web of Science ®Google Scholar
• Schiller JT, Lowy DR. Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials. J Infect Dis. 2009 Jul 15;200(2):166–171.
   PubMed Web of Science ®Google Scholar
• Pastrana DV, Buck CB, Pang YY, et al. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology. 2004 Apr 10;321(2):205–216.
   PubMed Web of Science ®Google Scholar
• Buck CB, Pastrana DV, Lowy DR, et al. Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods Mol Med. 2005;119:445–462.
   PubMedGoogle Scholar
• Sehr P, Rubio I, Seitz H, et al. High throughput pseudovirion-based neutralization assay for analysis of natural and vaccine-induced antibodies against human papillomaviruses. PLoS One. 2013;8:e75677.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Human papillomavirus laboratory manual. 1st ed. Geneva, Switzerland: WHO Press; 2010. [cited 2019 Apr]. Available from https://www.who.int/immunization/hpv/learn/hpv_laboratory_manual__who_ivb_2009_2010.pdf
   Google Scholar
• Opalka D, Matys K, Bojczuk P, et al. Multiplexed serologic assay for nine anogenital human papillomavirus types. Clin Vaccine Immunol. 2010 May;17(5):818–827.
   PubMedGoogle Scholar
• Brown DR, Garland SM, Ferris DG, et al. The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay. Hum Vaccin. 2011 Feb;7(2):230–238.
   PubMed Web of Science ®Google Scholar
• Roberts C, Green T, Hess E, et al. Development of a human papillomavirus competitive luminex immunoassay for 9 HPV types. Hum Vaccin Immunother. 2014;10(8):2168–2174.
   PubMed Web of Science ®Google Scholar
• Dessy FJ, Giannini SL, Bougelet CA, et al. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum Vaccin. 2008 Nov-Dec;4(6):425–434.
   PubMed Web of Science ®Google Scholar
• Robbins HA, Waterboer T, Porras C, et al. Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay. Hum Vaccin Immunother. 2014;10(10):2965–2974.
   PubMed Web of Science ®Google Scholar
• Robbins HA, Li Y, Porras C, et al. Glutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirus. BMC Infect Dis. 2014 Mar 3;14:120.
   PubMed Web of Science ®Google Scholar
• Waterboer T, Sehr P, Michael KM, et al. Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. Clin Chem. 2005 Oct;51(10):1845–1853.
   PubMed Web of Science ®Google Scholar
• Schiffman M, Safaeian M, Wentzensen N. The use of human papillomavirus seroepidemiology to inform vaccine policy. Sex Transm Dis. 2009 Nov;36(11):675–679.
   PubMed Web of Science ®Google Scholar
• Safaeian M, Porras C, Schiffman M, et al. Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and −18 infections. J Natl Cancer Inst. 2010 Nov 3;102(21):1653–1662.
   PubMedGoogle Scholar
• Lin SW, Ghosh A, Porras C, et al. HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays. PLoS One. 2013;8:e53067.
   PubMed Web of Science ®Google Scholar
• Carter JJ, Koutsky LA, Hughes JP, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis. 2000 Jun;181(6):1911–1919..
   PubMed Web of Science ®Google Scholar
• Beachler DC, Jenkins G, Safaeian M, et al. Natural acquired immunity against subsequent genital human papillomavirus infection: a systematic review and meta-analysis. J Infect Dis. 2016 May 1;213(9):1444–1454.
   PubMed Web of Science ®Google Scholar
• Dillner J, Arbyn M, Dillner L. Translational mini-review series on vaccines: monitoring of human papillomavirus vaccination. Clin Exp Immunol. 2007 May;148(2):199–207.
   PubMed Web of Science ®Google Scholar
• Malik ZA, Hailpern SM, Burk RD. Persistent antibodies to HPV virus-like particles following natural infection are protective against subsequent cervicovaginal infection with related and unrelated HPV. Viral Immunol. 2009 Dec;22(6):445–449.
   PubMed Web of Science ®Google Scholar
• Wentzensen N, Rodriguez AC, Viscidi R, et al. A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study. J Infect Dis. 2011 Jul 1;204(1):94–102.
   PubMed Web of Science ®Google Scholar
• Castellsagué X, Naud P, Chow SN, et al. Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA. J Infect Dis. 2014 Aug 15;210(4):517–534.
   PubMed Web of Science ®Google Scholar
• Safaeian M, Castellsagué X, Hildesheim A, et al. Risk of HPV-16/18 infections and associated cervical abnormalities in women seropositive for naturally acquired antibodies: pooled analysis based on control arms of two large clinical trials. J Infect Dis. 2018 Jun 5;218(1):84–94.
   PubMed Web of Science ®Google Scholar
• Lu B, Viscidi RP, Wu Y, et al. Prevalent serum antibody is not a marker of immune protection against acquisition of oncogenic HPV16 in men. Cancer Res. 2012 Feb 1;72(3):676–685.
   PubMed Web of Science ®Google Scholar
• de Gruijl TD, Bontkes HJ, Walboomers JM, et al. Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepithelial neoplasia. J Natl Cancer Inst. 1997 May 7;89(9):630–638.
   PubMedGoogle Scholar
• Kirnbauer R, Hubbert NL, Wheeler CM, et al. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst. 1994 Apr 6;86(7):494–499.
   PubMed Web of Science ®Google Scholar
• Bontkes HJ, de Gruijl TD, Walboomers JM, et al. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16. J Gen Virol. 1999;80(Pt 2):409–417..
   PubMedGoogle Scholar
• Lu B, Viscidi RP, Wu Y, et al. Seroprevalence of human papillomavirus (HPV) type 6 and 16 vary by anatomic site of HPV infection in men. Cancer Epidemiol Biomarkers Prev. 2012 Sep;21(9):1542–1546..
   PubMed Web of Science ®Google Scholar
• Giuliano AR, Viscidi R, Torres BN, et al. Seroconversion following anal and genital HPV infection in men: the HIM study. Papillomavirus Res. 2015 Dec 1;1:109–115.
   PubMed Web of Science ®Google Scholar
• Pamnani SJ, Sudenga SL, Viscidi R, et al. Impact of serum antibodies to HPV serotypes 6, 11, 16, and 18 to risks of subsequent genital HPV infections in men: the HIM study. Cancer Res. 2016 Oct 15;76(20):6066–6075.
   PubMed Web of Science ®Google Scholar
• Stone KM, Karem KL, Sternberg MR, et al. Seroprevalence of human papilloma virus type16 infection in the United States. J Infect Dis. 2002;186:1396–1402.
   PubMed Web of Science ®Google Scholar
• Markowitz LE, Sternberg M, Dunne EF, et al. Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003–2004. J Infect Dis. 2009;200:1059–1067.
   PubMed Web of Science ®Google Scholar
• Lu B, Viscidi RP, Lee JH, et al. Human papillomavirus (HPV) 6, 11, 16, and 18 seroprevalence is associated with sexual practice and age: results from the multinational HPV infection in men study (HIM Study). Cancer Epidemiol Biomarkers Prev. 2011;20:990–1002.
   PubMed Web of Science ®Google Scholar
• Palefsky JM. Human papillomavirus infection and anogenital neoplasia in human immunode?ciency virus-positive men and women. J Natl Cancer Inst Monogr. 1998;1998:15–20.
   Google Scholar
• Stanley M. HPV - immune response to infection and vaccination. Infect Agent Cancer. 2010;5:19.
   PubMedGoogle Scholar
• Mooij SH, Landén O, van der Klis FR, et al. No evidence for a protective effect of naturally induced HPV antibodies on subsequent anogenital HPV infection in HIV-negative and HIV-infected MSM. J Infect. 2014;69(4):375–386.
   PubMed Web of Science ®Google Scholar
• Beachler DC, Pinto LA, Kemp TJ, et al. An examination of HPV16 natural immunity in men who have sex with men (MSM) in the HPV in men (HIM) study. Cancer Epidemiol Biomarkers Prev. 2018 Apr;27(4):496–502.
   PubMed Web of Science ®Google Scholar
• Edelstein ZR, Carter JJ, Garg R, et al. Serum antibody response following genital {alpha}9 human papillomavirus infection in young men. J Infect Dis. 2011 Jul 15;204(2):209–216.
   PubMed Web of Science ®Google Scholar
• Mooij SH, Landén O, van der Klis FR, et al. HPV seroconversion following anal and penile HPV infection in HIV-negative and HIV-infected MSM. Cancer Epidemiol Biomarkers Prev. 2014;23(11):2455–2461..
   PubMed Web of Science ®Google Scholar
• van Rijn VM, Mooij SH, Mollers M, et al. Anal, penile, and oral high-risk HPV infections and HPV seropositivity in HIV-positive and HIV-negative men who have sex with men. PLoS One. 2014 Mar 20;9(3):e92208.
   PubMed Web of Science ®Google Scholar
• Zou H, Tabrizi SN, Grulich AE, et al. Antibody responses following incident anal and penile infection with human papillomavirus in teenage men who have sex with men. Int J Cancer. 2016 Aug 1;139(3):639–646.
   PubMed Web of Science ®Google Scholar
• Poynten IM, Waterboer T, Jin F, et al. Human papillomavirus seroprevalence and association with anal HPV infection and squamous intraepithelial lesions in Australian gay and bisexual men. Cancer Epidemiol Biomarkers Prev. 2018 Jul;27(7):768–775.
   PubMed Web of Science ®Google Scholar
• Heiligenberg M, Alberts CJ, Waterboer T, et al. Route of sexual exposure is independently associated with seropositivity to HPV-16 and HPV-18 among clients of an STI clinic in the Netherlands. J Infect Dis. 2013 Oct 1;208(7):1081–1085.
   PubMed Web of Science ®Google Scholar
• Vriend HJ, Bogaards JA, van der Klis FR, et al. Patterns of human papillomavirus DNA and antibody positivity in young males and females, suggesting a site-specific natural course of infection. PLoS One. 2013 Apr 23;8(4):e60696.
   PubMed Web of Science ®Google Scholar
• Strickler HD, Schiffman MH, Eklund C, et al. Evidence for at least two distinct groups of humoral immune reactions to papillomavirus antigens in women with squamous intraepithelial lesions. Cancer Epidemiol Biomarkers Prev. 1997 Mar;6(3):183–188.
   PubMed Web of Science ®Google Scholar
• Sasagawa T, Yamazaki H, Dong YZ, et al. Immunoglobulin-A and -G responses against virus-like particles (VLP) of human papillomavirus type 16 in women with cervical cancer and cervical intra-epithelial lesions. Int J Cancer. 1998 Feb 9;75(4):529–535.
   PubMed Web of Science ®Google Scholar
• Elfgren K, Bistoletti P, Dillner L, et al. Conization for cervical intraepithelial neoplasia is followed by disappearance of human papillomavirus deoxyribonucleic acid and a decline in serum and cervical mucus antibodies against human papillomavirus antigens. Am J Obstet Gynecol. 1996;174(3):937–942.
   PubMed Web of Science ®Google Scholar
• Ho L, Terry G, Mansell B, et al. Detection of DNA and E7 transcripts of human papillomavirus types 16, 18, 31 and 33, TGF-ß and GM-CSF transcripts in cervical cancers and precancers. Arch Virol. 1994;139(1–2):79–85.
   PubMed Web of Science ®Google Scholar
• Stavnezer J. Regulation of antibody production and class switching by TGF-ß. J Immunol. 1995;155:1647–1651.
   PubMed Web of Science ®Google Scholar
• Petter A, Heim K, Guger M, et al. Specific serum IgG, IgM and IgA antibodies to human papillomavirus types 6, 11, 16, 18 and 31 virus-like particles in human immunodeficiency virus-seropositive women. J Gen Virol. 2000 Mar;81(Pt 3):701–708..
   PubMedGoogle Scholar
• Carter JJ, Galloway DA. Humoral immune response to human papillomavirus infection. Clin Dermatol. 1997 Mar-Apr;15(2):249–259.
   PubMed Web of Science ®Google Scholar
• de Gruijl TD, Bontkes HJ, Walboomers JM, et al. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. I. Differential T-helper and IgG responses in relation to HPV infection and disease outcome. J Gen Virol. 1999 Feb;80(Pt 2):399–408.
   PubMedGoogle Scholar
• Cameron JE, Snowhite IV, Chaturvedi AK, et al. Human papillomavirus-specific antibody status in oral fluids modestly reflects serum status in human immunodeficiency virus-positive individuals. Clin Diagn Lab Immunol. 2003;10(3):431–438.
   PubMedGoogle Scholar
• Rocha-Zavaleta L, Pereira-Suarez AL, Yescas G, et al. Mucosal IgG and IgA responses to human papillomavirus type 16 capsid proteins in HPV16-infected women without visible pathology. Viral Immunol. 2003;16(2):159–168.
   PubMed Web of Science ®Google Scholar
• Bierl C, Karem K, Poon AC, et al. Correlates of cervical mucosal antibodies to human papillomavirus 16: results from a case control study. Gynecol Oncol. 2005 Dec;99(3 Suppl 1):S262–8..
   PubMed Web of Science ®Google Scholar
• Buchinsky FJ, Carter JJ, Wipf GC, et al. Comparison of oral fluid and serum ELISAs in the determination of IgG response to natural human papillomavirus infection in university women. J Clin Virol. 2006;35(4):450–453.
   PubMed Web of Science ®Google Scholar
• Wang Z, Hansson BG, Forslund O, et al. Cervical mucus antibodies against human papillomavirus type 16, 18, and 33 capsids in relation to presence of viral DNA. J Clin Microbiol. 1996 Dec;34(12):3056–3062..
   PubMed Web of Science ®Google Scholar
• Marais DJ, Best JM, Rose RC, et al. Oral antibodies to human papillomavirus type 16 in women with cervical neoplasia. J Med Virol. 2001 Sep;65(1):149–154.
   PubMed Web of Science ®Google Scholar
• Sasagawa T, Rose RC, Azar KK, et al. Mucosal immunoglobulin-A and -G responses to oncogenic human papilloma virus capsids. Int J Cancer. 2003 Apr 10;104(3):328–335.
   PubMed Web of Science ®Google Scholar
• Mbulawa ZZ, Williamson AL, Stewart D, et al. Association of serum and mucosal neutralizing antibodies to human papillomavirus type 16 (HPV-16) with HPV-16 infection and cervical disease. J Gen Virol. 2008 Apr;89(Pt 4):910–914.
   PubMedGoogle Scholar
• Hocini H, Barra A, Belec L, et al. Systemic and secretoryhumoral immunity in the normal human vaginal tract. Scand J Immunol. 1995;42:269–274.
   PubMed Web of Science ®Google Scholar
• Dillner L, Bekassy Z, Jonsson N, et al. Detection of IgA antibodies against human papillomavirus in cervical secretions from patients with cervical intraepithelial neoplasia. Int J Cancer. 1989;43:36–40.
   PubMed Web of Science ®Google Scholar
• Dillner L, Fredriksson A, Persson E, et al. Antibodies against papillomavirus antigens in cervical secretions from condyloma patients. J Clin Microbiol. 1993;31:192–197.
   PubMed Web of Science ®Google Scholar
• Dreyfus M, Baldauf -J-J, Ritter J, et al. Seric and local antibodies against a synthetic peptide of HPV16. Eur J Obstet Gynecol Reprod Biol. 1995;59:187–191.
   PubMed Web of Science ®Google Scholar
• Veress G, Kónya J, Csiky-Mészáros T, et al. Human papillomavirus DNA and anti-HPV secretory IgA antibodies in cytologically normal cervical specimens. J Med Virol. 1994;43:201–207.
   PubMed Web of Science ®Google Scholar
• Pattyn J, Van Keer S, Tjalma W, et al. Infection and vaccine-induced HPV-specific antibodies in cervicovaginal secretions. A review of the literature. Papillomavirus Res. 2019 Dec;8:100185..
   PubMed Web of Science ®Google Scholar
• Tjiong MY, Schegget JT, Tjiong-A-Hung SP, et al. IgG antibodies against human papillomavirus type 16, E7 proteins in cervicovaginal washing fluid from patients with cervical neoplasia. Int J Gynecol Cancer. 2000;10:296–304.
   PubMed Web of Science ®Google Scholar
• Tjiong MY, Zumbach K, Schegget JT, et al. Antibodies against human papillomavirus type 16 and 18 E6 and E7 proteins in cervicovaginal washings and serum of patients with cervical neoplasia. Viral Immunol. 2001;14:415–424.
   PubMed Web of Science ®Google Scholar
• Bélec L, Dupré T, Prazuck T, et al. Cervicovaginal overproduction of specific IgG to human immunodeficiency virus (HIV) contrasts with normal or impaired IgA local response in HIV infection. J Infect Dis. 1995 Sep;172(3):691–697.
   PubMed Web of Science ®Google Scholar
• Quesnel A, Cu-Uvin S, Murphy D, et al. Comparative analysis of methods for collection and measurement to immunoglobulins in cervical and vaginal secretions of women. J Immunol Methods. 1997;202:153–161.
   PubMed Web of Science ®Google Scholar
• Marais DJ, Vardas E, Ramjee G, et al. The impact of human immunodeficiency virus type 1 status on human papillomavirus (HPV) prevalence and HPV antibodies in serum and cervical secretions. J Infect Dis. 2000 Oct;182(4):1239–1242.
   PubMed Web of Science ®Google Scholar
• Passmore JA, Marais DJ, Sampson C, et al. Cervicovaginal, oral, and serum IgG and IgA responses to human papillomavirus type 16 in women with cervical intraepithelial neoplasia. J Med Virol. 2007 Sep;79(9):1375–1380.
   PubMed Web of Science ®Google Scholar
• Mestecky J. The common mucosal system and current strategies for induction of immune responses in external secretions. J Clin Immunol. 1987;7:265–276.
   PubMed Web of Science ®Google Scholar
• Dreyer G. Clinical implications of the interaction between HPV and HIV infections. Best Pract Res Clin Obstet Gynaecol. 2018 Feb;47:95–106.
   PubMed Web of Science ®Google Scholar
• Viscidi RP, Ahdieh-Grant L, Schneider MF, et al. Serum immunoglobulin A response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women. J Infect Dis. 2003 Dec 15;188(12):1834–1844.
   PubMed Web of Science ®Google Scholar
• Viscidi RP, Snyder B, Cu-Uvin S, et al. Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women. Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):283–288.
   PubMed Web of Science ®Google Scholar
• Marais DJ, Carrara H, Ramjee G, et al. HIV-1 seroconversion promotes rapid changes in cervical human papillomavirus (HPV) prevalence and HPV-16 antibodies in female sex workers. J Med Virol. 2009 Feb;81(2):203–210.
   PubMed Web of Science ®Google Scholar
• Namujju PB, Waterboer T, Banura C, et al. Risk of seropositivity to multiple oncogenic human papillomavirus types among human immunodeficiency virus-positive and -negative Ugandan women. J Gen Virol. 2011 Dec;92(Pt 12):2776–2783.
   PubMedGoogle Scholar
• Alberts CJ, van Rooijen MS, Prins M, et al. HIV is an important risk factor for human papillomavirus types 16 and 18 seropositivity among sexually active men who have sex with men. Sex Transm Dis. 2015 Mar;42(3):129–134.
   PubMed Web of Science ®Google Scholar
• Mooij SH, van der Klis FR, van der Sande MA, et al. Seroepidemiology of high-risk HPV in HIV-negative and HIV-infected MSM: the H2M study. Cancer Epidemiol Biomarkers Prev. 2013 Oct;22(10):1698–1708.
   PubMed Web of Science ®Google Scholar
• Stanley M, Gissmann L, Nardelli-Haefliger D. Immunobiology of human papillomavirus infection and vaccination - implications for second generation vaccines. Vaccine. 2008;26(Suppl 10):K62–7.
   PubMedGoogle Scholar
• Signorelli C, Odone A, Ciorba V, et al. Human papillomavirus 9-valent vaccine for cancer prevention: a systematic review of the available evidence. Epidemiol Infect. 2017 Jul;145(10):1962–1982.
   PubMed Web of Science ®Google Scholar
• Cheng MA, Farmer E, Huang C, et al. Therapeutic DNA vaccines for human papillomavirus and associated diseases. Hum Gene Ther. 2018 Sep;29(9):971–996.
   PubMed Web of Science ®Google Scholar
• Dadar M, Chakraborty S, Dhama K, et al. Advances in designing and developing vaccines, drugs and therapeutic approaches to counter human papilloma virus. Front Immunol. 2018 Nov 12;9:2478.
   PubMed Web of Science ®Google Scholar
• Mohsen MO, Zha L, Cabral-Miranda G, et al. Major findings and recent advances in virus-like particle (VLP)-based vaccines. Semin Immunol. 2017 Dec;34:123–132.
   PubMed Web of Science ®Google Scholar
• Zhou J, Sun XY, Stenzel DJ, et al. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology. 1991 Nov;185(1):251–257.
   PubMed Web of Science ®Google Scholar
• World Health Organization Expert Committee on Biological Standardization. Guidelines to assure the quality, safety and efficacy of recombinant human papillomavirus virus-like particle vaccines. Geneva: WHO; 2007. [cited 2019 Aug]. Available from: http://www.who.int/biologicals/publications/trs/areas/vaccines/human_papillomavirus/HPVg%20Final%20BS%202050%20.pdf
   Google Scholar
• World Health Organization. WHO meeting on the standardization of HPV assays and the role of WHO HPV LabNet in supporting vaccine introduction. Geneva: WHO; 2008. [cited 2019 Aug]. Available from: http://www.who.int/biologicals/areas/vaccines/hpv_labnet/FINAL%20repor_%20HPV_%2023+24%20+25%20Jan%202008%20_CLEAN_.pdf
   Google Scholar
• Frazer IH. Measuring serum antibody to human papillomavirus following infection or vaccination. Gynecol Oncol. 2010 Jun;118(1 Suppl):S8–11.
   PubMedGoogle Scholar
• Gonçalves AK, Giraldo PC, Farias KJ, et al. Characterization of immunoglobulin A/G responses during 3 doses of the human papillomavirus-16/18 ASO4-adjuvanted vaccine. Sex Transm Dis. 2016 May;43(5):335–339.
   PubMed Web of Science ®Google Scholar
• Dawar M, Deeks S, Dobson S. Human papillomavirus vaccines launch a new era in cervical cancer prevention. CMAJ. 2007 Aug 28;177(5):456–461.
   PubMed Web of Science ®Google Scholar
• Scherpenisse M, Mollers M, Schepp RM, et al. Detection of systemic and mucosal HPV-specific IgG and IgA antibodies in adolescent girls one and two years after HPV vaccination. Hum Vaccin Immunother. 2013;9(2):314–321.
   PubMed Web of Science ®Google Scholar
• Schwarz TF, Kocken M, Petäjä T, et al. Correlation between levels of human papillomavirus (HPV)-16 and 18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine. Hum Vaccin. 2010 Dec;6(12):1054–1061..
   PubMed Web of Science ®Google Scholar
• Nakalembe M, Banura C, Namujju PB, et al. The levels of anti-HPV16/18 and anti-HPV31/33/35/45/52/58 antibodies among AS04-adjuvanted HPV16/18 vaccinated and non-vaccinated Ugandan girls aged 10-16 years. Infect Agent Cancer. 2014 Sep 1;9:29.
   PubMed Web of Science ®Google Scholar
• Handisurya A, Schellenbacher C, Haitel A, et al. Human papillomavirus vaccination induces neutralising antibodies in oral mucosal fluids. Br J Cancer. 2016 Feb 16;114(4):409–416.
   PubMed Web of Science ®Google Scholar
• Li Z, Palaniyandi S, Zeng R, et al. Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection. Proc Natl Acad Sci U S A. 2011 Mar 15;108(11):4388–4393.
   PubMed Web of Science ®Google Scholar
• Naz RK. Female genital tract immunity: distinct immunological challenges for vaccine development. J Reprod Immunol. 2012 Jan;93(1):1–8.
   PubMed Web of Science ®Google Scholar
• Balmelli C, Roden R, Potts A, et al. Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions. J Virol. 1998 Oct;72(10):8220–8229.
   PubMed Web of Science ®Google Scholar
• Fraillery D, Zosso N, Nardelli-Haefliger D. Rectal and vaginal immunization of mice with human papillomavirus L1 virus-like particles. Vaccine. 2009 Apr 14;27(17):2326–2334.
   PubMed Web of Science ®Google Scholar
• Mugo N, Ansah NA, Marino D, et al. Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa. Hum Vaccin Immunother. 2015;11(6):1323–1330.
   PubMed Web of Science ®Google Scholar
• Huh WK, Joura EA, Giuliano AR, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial. Lancet. 2017 Nov 11;390(10108):2143–2159.
   PubMed Web of Science ®Google Scholar
• Huang T, Liu Y, Li Y, et al. Evaluation on the persistence of anti-HPV immune responses to the quadrivalent HPV vaccine in Chinese females and males: up to 3.5?years of follow-up. Vaccine. 2018 Mar 7;36(11):1368–1374.
   PubMed Web of Science ®Google Scholar
• Ruiz-Sternberg ÁM, Moreira ED Jr, Restrepo JA, et al. Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women. Papillomavirus Res. 2018 Jun;5:63–74.
   PubMed Web of Science ®Google Scholar
• Godi A, Bissett SL, Miller E2, et al. Relationship between humoral immune responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 year old girls receiving Cervarix® or Gardasil® vaccine. PLoS One. 2015 Oct 23;10(10):e0140926.
   PubMed Web of Science ®Google Scholar
• Leung TF, Liu AP, Lim FS, et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: results to month 12 from a randomized trial. Hum Vaccin Immunother. 2015;11(7):1689–1702..
   PubMed Web of Science ®Google Scholar
• Einstein MH, Levin MJ, Chatterjee A, et al. Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: follow-up through month 48 in a Phase III randomized study. Hum Vaccin Immunother. 2014;10(12):3455–3465.
   PubMed Web of Science ®Google Scholar
• Leung TF, Liu AP, Lim FS, et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9-14?years: results to month 36 from a randomized trial. Vaccine. 2018 Jan 2;36(1):98–106.
   PubMed Web of Science ®Google Scholar
• Safaeian M, Porras C, Pan Y, et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res (Phila). 2013 Nov;6(11):1242–1250.
   PubMed Web of Science ®Google Scholar
• Naud PS, Roteli-Martins CM, De Carvalho NS, et al. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccin Immunother. 2014;10(8):2147–2162.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Brodszki N, van Damme P, et al. A randomized, double-blind, Phase III study of the immunogenicity and safety of a 9-valent human papillomavirus L1 virus-like particle vaccine (V503) versus Gardasil® in 9-15-year-old girls. Pediatr Infect Dis J. 2015 Sep;34(9):992–998..
   PubMed Web of Science ®Google Scholar
• Petäjä T, Pedersen C, Poder A, et al. Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young women. Int J Cancer. 2011 Nov 1;129(9):2147–2157.
   PubMed Web of Science ®Google Scholar
• Schwarz TF, Galaj A, Spaczynski M, et al. Ten-year immune persistence and safety of the HPV-16/18 AS04-adjuvanted vaccine in females vaccinated at 15-55 years of age. Cancer Med. 2017 Nov;6(11):2723–2731.
   PubMed Web of Science ®Google Scholar
• Olsson SE, Villa LL, Costa RL, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine. 2007 Jun 21;25(26):4931–4939.
   PubMed Web of Science ®Google Scholar
• Nygård M, Saah A, Munk C, et al. Evaluation of the long-term anti-human papillomavirus 6 (HPV6), 11, 16, and 18 immune responses generated by the quadrivalent HPV vaccine. Clin Vaccine Immunol. 2015 Aug;22(8):943–948.
   PubMedGoogle Scholar
• Guevara A, Cabello R, Woelber L, et al. Antibody persistence and evidence of immune memory at 5years following administration of the 9-valent HPV vaccine. Vaccine. 2017 Sep 5;35(37):5050–5057.
   PubMed Web of Science ®Google Scholar
• Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29:4294–4301.
   PubMed Web of Science ®Google Scholar
• Parker KH, Kemp TJ, Pan Y, et al. Evaluation of HPV-16 and HPV-18 specific antibody measurements in saliva collected in oral rinses and merocel® sponges. Vaccine. 2018;36(19):2705–2711.
   PubMed Web of Science ®Google Scholar
• Parker KH, Kemp TJ, Isaacs-Soriano K, et al. HPV-specific antibodies at the oral cavity up to 30?months after the start of vaccination with the quadrivalent HPV vaccine among mid-adult aged men. Vaccine. 2019;37(21):2864–2869.
   PubMed Web of Science ®Google Scholar
• Pinto LA, Kemp TJ, Torres BN, et al. Quadrivalent human papillomavirus (HPV) vaccine induces HPV-specific antibodies in the oral cavity: results from the Mid-Adult Male Vaccine Trial. J Infect Dis. 2016;214(8):1276–1283.
   PubMed Web of Science ®Google Scholar
• Szarewski A, Skinner SR, Garland S. Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low risk HPV types (PATRICIA randomised trial): an unexpected observation. J Infect Dis. 2013;208:1391–1396.
   Google Scholar
• Howell-Jones R, Soldan K, Wetten S, et al. Declining genital warts in young women in England associated with HPV 16/18 vaccination: an ecological study. J Infect Dis. 2013;208:1397–1403.
   PubMed Web of Science ®Google Scholar
• Kjaer SK, Sigurdsson K, Iversen OE, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila). 2009;2:868–878.
   PubMed Web of Science ®Google Scholar
• Paavonen J, Naud P, Salmerón J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009 Jul 25;374(9686):301–314.
   PubMed Web of Science ®Google Scholar
• Luckett R, Feldman S. Impact of 2-, 4- and 9-valent HPV vaccines on morbidity and mortality from cervical cancer. Hum Vaccin Immunother. 2016 Jun 2;12(6):1332–1342.
   PubMed Web of Science ®Google Scholar
• St Laurent J, Luckett R, Feldman S. HPV vaccination and the effects on rates of HPV-related cancers. Curr Probl Cancer. 2018 Sep;42(5):493–506.
   PubMed Web of Science ®Google Scholar
• Dillner J, Kjaer SK, Wheeler CM, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ. 2010;341:c3493.
   PubMed Web of Science ®Google Scholar
• Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007 May 10;356(19):1928–1943.
   PubMed Web of Science ®Google Scholar
• Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med. 2011 Feb 3;364(5):401–411.
   PubMed Web of Science ®Google Scholar
• Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011;365(17):1576–1585..
   PubMed Web of Science ®Google Scholar
• Wang X, Huang X, Zhang Y. Involvement of human papillomaviruses in cervical cancer. Front Microbiol. 2018 Nov 28;9:2896.
   PubMed Web of Science ®Google Scholar
• Fairley CK, Hocking JS, Gurrin LC, et al. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect. 2009;85:499–502.
   PubMed Web of Science ®Google Scholar
• Donovan B, Franklin N, Guy R, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis. 2011;11(1):39–44.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Human papillomavirus vaccines: WHO position paper, May 2017; Grading of scientific evidence (males). Wkly Epidemiol Rec. 2017;92(19):241–268.
   PubMedGoogle Scholar
• Lacey CJ. HPV vaccination in HIV infection. Papillomavirus Res. 2019 Jun 25;8:100174.
   PubMed Web of Science ®Google Scholar
• Arbyn M, Xu L, Simoens C, et al. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2018 May 9;5:CD009069.
   PubMed Web of Science ®Google Scholar
• Skinner SR, Szarewski A, Romanowski B, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet. 2014 Dec 20;384(9961):2213–2227.
   PubMed Web of Science ®Google Scholar
• Schwarz T, Spaczynski M, Kaufmann A, et al. Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15-55 years and first-time modelling of antibody responses in mature women: results from an open-label 6-year follow-up study. BJOG. 2015 Jan;122(1):107–118.
   PubMed Web of Science ®Google Scholar
• Villa LL, Ault KA, Giuliano AR, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine. 2006 Jul 7;24(27–28):5571–5583.
   PubMed Web of Science ®Google Scholar
• Olsson SE, Kjaer SK, Sigurdsson K, et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin. 2009 Oct;5(10):696–704.
   PubMed Web of Science ®Google Scholar
• Bhatla N, Suri V, Basu P, et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women. J Obstet Gynaecol Res. 2010 Feb;36(1):123–132.
   PubMed Web of Science ®Google Scholar
• Tumban E, Peabody J, Peabody DS, et al. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2. PLoS One. 2011;6(8):e23310.
   PubMed Web of Science ®Google Scholar
• Tyler M, Tumban E, Dziduszko A, et al. Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing. Vaccine. 2014 Jul 23;32(34):4267–4274.
   PubMed Web of Science ®Google Scholar
• Tyler M, Tumban E, Peabody DS, et al. The use of hybrid virus-like particles to enhance the immunogenicity of a broadly protective HPV vaccine. Biotechnol Bioeng. 2014 Dec;111(12):2398–2406.
   PubMed Web of Science ®Google Scholar
• Tyler M, Tumban E, Chackerian B. Second-generation prophylactic HPV vaccines: successes and challenges. Expert Rev Vaccines. 2014 Feb;13(2):247–255.
   PubMed Web of Science ®Google Scholar
• Boxus M, Fochesato M, Miseur A, et al. Broad cross-protection is induced in preclinical models by a human papillomavirus vaccine composed of L1/L2 chimeric virus-like particles. J Virol. 2016 Jun 24;90(14):6314–6325.
   PubMed Web of Science ®Google Scholar
• Hunter Z, Tumban E, Dziduszko A, et al. Aerosol delivery of virus-like particles to the genital tract induces local and systemic antibody responses. Vaccine. 2011 Jun 20;29(28):4584–4592.
   PubMed Web of Science ®Google Scholar
• McKay PF, Mann JF, Pattani A, et al. Intravaginal immunisation using a novel antigen-releasing ring device elicits robust vaccine antigen-specific systemic and mucosal humoral immune responses. J Control Release. 2017 Mar 10;249:74–83.
   PubMed Web of Science ®Google Scholar
• Singh B, Maharjan S, Sindurakar P, et al. Needle-free immunization with Chitosan-based systems. Int J Mol Sci. 2018 Nov 19;19(11):pii, E3639.
   Web of Science ®Google Scholar
• D’Addario M, Redmond S, Scott P, et al. Two-dose schedules for human papillomavirus vaccine: systematic review and meta-analysis. Vaccine. 2017 May 19;35(22):2892–2901.
   PubMed Web of Science ®Google Scholar
• Meites E, Kempe A, Markowitz LE. Use of a 2-dose schedule for human papillomavirus vaccination - Updated recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2016 Dec 16;65(49):1405–1408.
   PubMed Web of Science ®Google Scholar
• Sankaranarayanan R, Prabhu PR, Pawlita M, et al. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study. Lancet Oncol. 2016 Jan;17(1):67–77..
   PubMed Web of Science ®Google Scholar